The importance of studying history: Lessons learnt from a trial of tacrolimus in myasthenia gravis

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 82, Issue 9, 2011, Pages 945-

  Benatar, Michael ^a   Sanders, Donald ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; TACROLIMUS;

CONSENSUS; CYTOKINE PRODUCTION; DRUG EFFICACY; EDITORIAL; HUMAN; LOW DRUG DOSE; MYASTHENIA GRAVIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STUDY DESIGN;

ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; MYASTHENIA GRAVIS; PREDNISONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TACROLIMUS;

EID: 80051505712     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2011.243931     Document Type: Editorial

References (3)

1. Yoshikawa H, Kiuchi T, Saida T, et al. Randomised, double blind, placebo controlled study of tacrolimus in myasthenia gravis. J Neurol Neurosurg Psychiatry 2011;82:970-7.
2. Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. The Myasthenia Gravis Study Group. Neurology 1998;50:1778-83. (Pubitemid 28283251)
3. Sanders DB, Hart IK, Mantegazza R, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 2008;71:400-6.